Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage 3 melanoma remained alive, according to new results from a study led by researchers at the University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center has launched a $2.5 billion comprehensive philanthropic campaign: Only Possible Here, The Campaign to End Cancer.
